IL-17 and IL-23 Inhibitors in Moderate to Severe Plaque Psoriasis as Part of Current Therapeutic Strategies
The therapeutic landscape of plaque psoriasis has significantly changed over the past two decades due to the development of monoclonal antibodies that specifically target disease-relevant signaling pathways. Inhibitors of interleukins IL-17 and IL-23 play a crucial role in the treatment of moderate...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-07-01
|
| Series: | healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| Online Access: | https://doi.org/10.36000/hbT.2024.13.002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|